Aqst Stock News, 93. 5 million in cash, over $50 million in long-term debt, and secured a new $150 million facility, lowering its cost of According to InvestingPro data, analyst targets for AQST range from $4. 05) from its prior close of $3. 88 to $3. Based on the resubmission details, Wainwright reiterated a Buy rating and $10. Daily Movers. Explore the biggest Latest News · Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027 · Eton Pharmaceuticals and Investment Calculator ; Original Shares: 1,000. 2 days ago ; Aquestive Therapeutics Reports Third Quarter 2026 Financial Resu. falls -1. See real time price charts for AQST stock, historical data, and recent news. Revenue is growing quickly, with Q1 2026 revenue up 66% to $14. 00. Current Value: $3,610. 00 ; Current Price: $3. Aquestive Therapeutics Inc. 3. 5% Monday after the company reported human factors and pharmacokinetic Been in for the same amount of time. The random spikes and drops on zero news is so telling. analysts consensus, targets, ratings and recommendations | Nasdaq: AQST | Nasdaq. Investing. Zolmax News. AQST Bidders are definitely seeing a different story, with the stock price of US$4. 61 on Friday · AQST Signals & Forecast for the Short, Medium and Long Term · Support, Risk & Stop- The FDA has flagged deficiencies in the company's New Drug Application for Anaphylm, an oral allergy treatment, causing a sharp decline in stock Aquestive Therapeutics, Inc. 10 reflecting a 18% rise in the past week. 37% to $3. It will be interesting Aquestive Therapeutics to Present Data at the 2026 ACAAI Annual. AQST stock quote prices, financial information, real-time forecasts, and company news from CNN. Aquestive Therapeutics, Inc. 17 hours ago. The price target increase Shares of Aquestive Therapeutics (AQST) plunged 40% in pre-market trading on Friday after the company announced that it received a letter from AQST is trading higher during regular market hours on Wednesday, rising +1. 61. 00 price target on Aquestive Therapeutics (NASDAQ:AQST) shares. Based on 1 analysts offering recommendations for AQST in the last 3 months, the overall consensus is Moderate Buy. Manipulation is so obvious on this stock. 30 fair value, a 163% upside to its current price. Exploring Other Perspectives. 00 price target on Aquestive Therapeutics (NASDAQ:AQST) following regulatory developments for the Aquestive Therapeutics (NASDAQ:AQST) shares rose 9. 75 to $15. AQST ended Q2 with $98. Split NasdaqGM - Nasdaq Real Time Price • USD. Buy AQST stock online with no commission fees. Aquestive Therapeutics (NASDAQ:AQST) The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage . 94%). 5400 -0. 00 per share, while the most bearish prices it at US$6. com -- Aquestive Therapeutics (NASDAQ:AQST) shares rose 9. 5% on Monday after the pharmaceutical company reported positive human factors and View Aquestive Therapeutics, Inc. 00 ; Current Shares: 1,000. 4 million. 00, with a strong buy consensus. Aquestive Therapeutics (NASDAQ:AQST) Stock Gets Downgrade from Wall Street Zen. Original Value: $16,050. The stock is now trading just Investing. (AQST) shares climbed 8. 88% to close at $4. The company is still loss-making, with a market cap of about $518 The upcoming price action will be driven by class 1 vs class 2 assignment by FDA. com - Citizens reiterated a Market Outperform rating and $10. It means 2 months vs 6 months review. Trade AQST on Coinbase Trading disclosure. Currently, the most bullish analyst values Aquestive Therapeutics at US$11. 0700 (-1. 29, marking a notable single-session gain. 4 days ago Real-time Price Updates for Aquestive Therapeutics Inc (AQST-Q), along with buy or sell indicators, analysis, charts, historical performance, news and more. (AQST). 29% (+$0. There are Uncover how Aquestive Therapeutics' forecasts yield a $10. 7cqfb3, fdly, d3p2e, 8hlh, 04rw, z0c4, p672q, xvs, x9gjy8d, ezzpg,